Chemotherapy for metastatic castrate-sensitive prostate cancer

Background:the role of docetaxel chemotherapy in combination with androgen deprivation therapy for metastatic castrate-sensitive prostate cancer is emerging.methods:we reviewed the results from the pivotal randomized phase iii trials in this area: getug15, chaarted and stampede.results:all three studies demonstrated a benefit in progression-free survival with the use of docetaxel. however, two of the studies demonstrated a clinically meaningful overall survival benefit (chaarted and stampede), whereas the getug15 study did not demonstrate a major benefit.conclusions:docetaxel is an important option to consider for men who are fit for chemotherapy with newly diagnosed metastatic prostate cancer commencing androgen deprivation therapy.